Pipeline — registered trials by phase
No registered trials in this stage.
A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers
— · Healthy · Completed · est. 2012-11
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
— · Melanoma, Non-small Cell Lung Cancer, Breast Cancer · Completed · est. 2022-09-13
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
— · Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer · Completed · est. 2023-04-06
A Phase 1 Study of CDX-0159
— · Healthy Subjects · Completed · est. 2020-04-06
A Study of CDX-0159 in Patients With Prurigo Nodularis
— · Prurigo Nodularis · Completed · est. 2023-07-31
Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
— · Breast Cancer, Colorectal Cancer, Pancreatic Cancer · Completed · est. 2009-05
A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients
— · Squamous Cell Carcinoma of the Head and Neck · Completed · est. 2016-09-22
A Study of CDX-622 in Participants With Mild to Moderate Asthma
— · Mild to Moderate Asthma · Recruiting · est. 2027-03
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
— · CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma · Completed · est. 2015-12
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
— · Advanced Cancer · Completed · est. 2017-05-25
A Phase I Study of CDX-622
— · Healthy Participants · Completed · est. 2026-04-24
A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects
— · Healthy Subjects · Completed · est. 2022-01-14
A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
— · Chronic Spontaneous Urticaria · Completed · est. 2023-01-17
A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria
— · Cold Urticaria, Cold Contact Urticaria, Symptomatic Dermographism · Completed · est. 2022-12-16
A Study of CDX-585 in Patients With Advanced Malignancies
— · Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer · Completed · est. 2025-05-21
A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors
— · Advanced Cancer · Completed · est. 2018-01-30
A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
— · Breast Cancer, Colorectal Cancer, Pancreatic Cancer · Completed · est. 2010-05
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
— · Thyroid Cancer · Completed · est. 2016-10-13
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
— · Metastatic gpNMB Over-expressing Triple Negative Breast Cancer · Completed · est. 2017-11-30
Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
— · Malignant Glioma · Completed · est. 2010-11
A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
— · Eosinophilic Esophagitis · Completed · est. 2025-06-04
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
— · Breast Cancer · Completed · est. 2012-10
A Study of Barzolvolimab in Patients With Prurigo Nodularis
— · Prurigo Nodularis · Active Not Recruiting · est. 2026-03-17
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
— · Advanced Malignancies · Completed · est. 2012-06
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
— · Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma · Completed · est. 2015-04
A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
— · Chronic Inducible Urticaria · Completed · est. 2024-06-12
A Study of Barzolvolimab in Patients With Atopic Dermatitis
— · Atopic Dermatitis · Active Not Recruiting · est. 2026-05-06
A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
— · Chronic Spontaneous Urticaria · Completed · est. 2023-09-28
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
— · Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed · Completed · est. 2018-12-12
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
— · Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria · Recruiting · est. 2028-06
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
— · Chronic Spontaneous Urticaria · Enrolling By Invitation · est. 2028-09
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
— · Chronic Spontaneous Urticaria · Active Not Recruiting · est. 2026-10
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
— · Chronic Spontaneous Urticaria · Active Not Recruiting · est. 2026-10
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
— · Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma · Completed · est. 2016-11
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Celldex is lead sponsor; 34 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- SCHEDULE 13G/A2026-10-07SCHEDULE 13G/A
- 8-K2026-09-22Current report (material event)
- SCHEDULE 13G/A2026-08-14SCHEDULE 13G/A
- SCHEDULE 13G2026-08-14SCHEDULE 13G
- 10-Q2026-08-06Quarterly report
- 8-K2026-08-06Current report (material event)
- 8-K2026-07-15Current report (material event)
- S-82026-06-26Employee stock plan
- 8-K2026-06-26Current report (material event)
- SCHEDULE 13G/A2026-05-15SCHEDULE 13G/A
- SCHEDULE 13G/A2026-05-15SCHEDULE 13G/A
- SCHEDULE 13G2026-05-12SCHEDULE 13G
- 10-Q2026-05-07Quarterly report
- 8-K2026-05-07Current report (material event)
- SCHEDULE 13G/A2026-05-06SCHEDULE 13G/A
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- ARS2026-04-29Annual report to holders
- DEF 14A2026-04-29Proxy statement
- 424B52026-04-02Prospectus (offering)
- 8-K2026-04-02Current report (material event)
- 424B52026-04-01Prospectus (offering)
- SCHEDULE 13G/A2026-03-26SCHEDULE 13G/A
- SCHEDULE 13G/A2026-03-10SCHEDULE 13G/A
- 10-K2026-02-25Annual report
- 8-K2026-02-25Current report (material event)
- SCHEDULE 13G/A2026-02-10SCHEDULE 13G/A
- SCHEDULE 13G2026-02-09SCHEDULE 13G
- SCHEDULE 13G2025-11-14SCHEDULE 13G
- SCHEDULE 13G/A2025-11-14SCHEDULE 13G/A
- SCHEDULE 13G/A2025-11-14SCHEDULE 13G/A
- 10-Q2025-11-10Quarterly report
- 8-K2025-11-10Current report (material event)
- SCHEDULE 13G/A2025-11-07SCHEDULE 13G/A
- 8-K2025-08-19Current report (material event)
- SCHEDULE 13G/A2025-08-14SCHEDULE 13G/A
- SCHEDULE 13G/A2025-08-12SCHEDULE 13G/A
- 10-Q2025-08-07Quarterly report
- 8-K2025-08-07Current report (material event)
- SCHEDULE 13G2025-07-10SCHEDULE 13G
- S-82025-06-06Employee stock plan
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.